Clinical Trial Update: Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD [Phase 2]

View source ↗

Summary

Phase 2 efficacy and safety study of iSONEP with or without anti-VEGF therapies (Lucentis, Avastin, Eylea) for wet age-related macular degeneration; trial compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Avastin (bevacizumab)
• EYLEA (Aflibercept)
• Lucentis (ranibizumab)
• iSONEP (Sonepcizumab)

Snippet

Sponsor: Lpath, Inc. | Conditions: Exudative Age-related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2016-10-17